Cargando…

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice

Anti-factor VIII (FVIII) antibodies is a major complication of FVIII replacement therapy for hemophilia A. We investigated the immune response to recombinant human factor VIII Fc (rFVIIIFc) in comparison to BDD-rFVIII and full-length rFVIII (FL-rFVIII) in hemophilia A mice. Repeated administration o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishnamoorthy, Sriram, Liu, Tongyao, Drager, Douglas, Patarroyo-White, Susannah, Chhabra, Ekta Seth, Peters, Robert, Josephson, Neil, Lillicrap, David, Blumberg, Richard S., Pierce, Glenn F., Jiang, Haiyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936482/ https://www.ncbi.nlm.nih.gov/pubmed/26775174 http://dx.doi.org/10.1016/j.cellimm.2015.12.008

Ejemplares similares

Bleeding management: rFVIIIFc in hemophilia A and liver transplantation
por: Grottke, Oliver, et al.
Publicado: (2023)

Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
por: Giraud, Romain, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
por: Bullement, Ash, et al.
Publicado: (2019)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study
por: Oldenburg, Johannes, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
por: Bullement, Ash, et al.
Publicado: (2021)

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials
por: Klamroth, Robert, et al.
Publicado: (2021)

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes
por: van der Flier, Arjan, et al.
Publicado: (2015)

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study
por: Pasi, John, et al.
Publicado: (2022)

Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor
por: Georgescu, Maria T., et al.
Publicado: (2020)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity
por: Buyue, Yang, et al.
Publicado: (2014)

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates
por: Milani, Michela, et al.
Publicado: (2022)

Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood. 2022;139(26):3699-3707.
Publicado: (2023)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

A Novel Cell-Sheet Technology That Achieves Durable Factor VIII Delivery in a Mouse Model of Hemophilia A
por: Tatsumi, Kohei, et al.
Publicado: (2013)

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms
por: Georgescu, Maria T., et al.
Publicado: (2018)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice
por: Lundgren, Taran S., et al.
Publicado: (2022)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

Future prospects for the treatment of hemophilia: A global perspective
por: Lillicrap, David
Publicado: (2018)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein
por: PETERS, R T, et al.
Publicado: (2013)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Hemophilia Gene Therapy: Approaching the First Licensed Product
por: Batty, Paul, et al.
Publicado: (2021)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
por: Owaidah, Tarek M., et al.
Publicado: (2020)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
por: Scott, David W., et al.
Publicado: (2020)

To clear or to fear: An innate perspective on factor VIII immunity
por: Lai, Jesse Derek, et al.
Publicado: (2016)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eois6g6u1ssgcrc5vc1d2qv0hc